期刊文献+

贵州省维持性血透患者CKD-MBD单中心、横断面分析

原文传递
导出
摘要 目的 了解维持性血液透析患者矿物质及骨代谢异常(CKD-MBD)控制情况,并分析不同年龄组患者CKD-MBD 的不同.方法 选我院血液净化中心维持性血液透析〉3 月的276 例患者,分别检测其透析前血清钙、磷、全段甲状旁腺激素(iPTH)、碱性磷酸酶(ALP)、25-羟维生素D(25(OH)D)水平.结果 各年龄组血钙无差别;血磷20 组高于40-59 岁组及60 岁以上组;ALP 及25(OH)D 组各组间无显著差异;iPTH20-39岁组显著高于40-59 岁组及60 岁以上组. 结论 多数维持性血液透析患者矿物质及骨代谢控制不佳,达标率较低,其中20-39 岁青年患者血磷及iPTH 水平明显高于40 岁以上中老年患者,提示其血磷控制差,主要为高转运肾性骨病.
出处 《中华临床医师杂志(电子版)》 CAS 2016年第7期93-94,共2页 Chinese Journal of Clinicians(Electronic Edition)
  • 相关文献

参考文献5

  • 1朱萍,吴佳珺,汪关煜,钱莹,齐进,顾志冬,谢静远,陈楠.肾性骨营养不良的组织学检查及非侵入性检测的临床意义[J].中华肾脏病杂志,2008,24(5):309-314. 被引量:11
  • 2Danese MD,Kim J,Doan QV,et al.PTH and the risks forhip,vertebral,and pelvic fractures among patients on dialysis.AmJ Kidney Dis,2006,47(1):149-156.
  • 3Kendrick J,Chonchol M.The role of phosphorus in the development andprogression of vascular calcification. Am J KidneyDis,2011,58(5):826-834.
  • 4Adeney KL,Siscovick DS,Ix JH,et al.Association of serum phosphatewith vascular and valscular and valvular calcification in moderateCKD.J Am Soc Nephrol,2009,20(2);381-387.
  • 5Moallem E,Kilav R,Silver J,et al.RNA-Protein binding andpost-transcriptional regulation of parathyroid hormone geneexpression by calcium and phosphate.J Biol Chem,1998,273:5253-5259.

二级参考文献14

  • 1Wang M, Hercz G, Sherrard DJ, et al. Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity. Am J Kidney Dis, 1995,26:836-844.
  • 2Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology, 2001,142:5050-5055.
  • 3Smith AJ, Faugere MC, Abreo K,et al. Aluminum-erlated bone disease in mild and advanced renal failure: evidence for high prevalence and morbidity and studies on etiology and diagnosis. Am J Nephrol, 1986,6:275-283.
  • 4Krapn D, Lajtman Z, Erceg I, et al. Renal osteodystrophy based on bone histomorphometry: 20 years of experience. Dial Transplant, 2004,33:476-482.
  • 5Malluche HH, Monier-Faugere MC. Understanding and managing hyperphosphatemia in patients with chronic renal disease. Clin Nephrol, 1999,52:267-277.
  • 6Lewin E, Olgaard K. Influence of parathyroid mass on the regulation of PTH secretion. Kidney Int Suppl, 2006,(102): S16-S21.
  • 7Monier-Faugere MC, Geng Z, Mawad H, et al. Improved assessment of bone turnover by the PTH-(1-84)/large CPTH fragments ratio in ESRD patients. Kidney Int, 2001,60: 1460-1468.
  • 8Slatopolsky E, Finch J, Clay P, et al. A novel mechanism for skeletal resistance in uremia. Kidney Int, 2000,58:753- 761.
  • 9Coen G, Ballanti P, Balducci A, et al. Serum osteoprotegerin and renal osteodystrophy. Nephrol Dial Transplant, 2002,17:233-238.
  • 10Haas M, Leko-Mohr Z, Roschger P, et al. Osteoprotegerin and parathyroid hormone as markers of high-turnover osteodystrophy and decreased bone mineralization in hemodialysis patients. Am J Kidney Dis, 2002,39:580-586.

共引文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部